Invasive Saccharomyces Infection: A Comprehensive Review
The DOI matches its Crossref record; 87 of the 88 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Saccharomyces cerevisiae (also known as "baker's yeast" or "brewer's yeast") is mostly considered to be an occasional digestive commensal. However, since the 1990s, there have been a growing number of reports about its implication as an etiologic agent of invasive infection. A particular feature of such infections is their association with a probiotic preparation of Saccharomyces boulardii (a subtype of S. cerevisiae) for treatment various diarrheal disorders. METHODS: We collected published case reports, through May 2005, of invasive Saccharomyces infection by use of a Medline query. Epidemiological and clinical charts and therapeutic strategies were analyzed. RESULTS: We found 92 cases of Saccharomyces invasive infection. Predisposing factors were similar to those of invasive candidiasis, with intravascular catheter and antibiotic therapy being the most frequent. Blood was the most frequent site of isolation (for 72 patients). S. boulardii accounted for 51.3% of fungemias and was exclusively isolated from blood. Compared with patients infected with S. cerevisiae, patients infected with S. boulardii were more frequently immunocompetent and had a better prognosis. Saccharomyces invasive infection was clinically indistinguishable from an invasive candidiasis. Overall, S. cerevisiae clinical isolates exhibited low susceptibility to amphotericin B and azole derivatives. However, global outcome was favorable in 62% of the cases. Treatment with intravenous amphotericin B and fluconazole, in combination with central vascular catheter removal, were effective therapeutic options. CONCLUSION: Saccharomyces organisms should now be added to the growing list of emerging fungal pathogens. Special caution should be taken regarding the use of S. boulardii probiotic preparations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Multiple cases of disseminated infection have been identified in apparent association with this probiotic, particularly in immune-suppressed individuals (39).”
From The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies (2018) · cites this paper as [39]
In the citing paper
“In a few case studies, however, S. cerevisiae has been implicated in catheter-associated infections with mixed-species biofilms in patients in intensive care units (ICUs)”
From Candida albicans Biofilms and Human Disease (2015) · cites this paper as [50]
In the citing paper
“and it is able to form a thin biofilm consisting of round, budding yeast-form cells and pseudohyphal cells in vitro (26, 50, 128, 164).”
From Candida albicans Biofilms and Human Disease (2015) · cites this paper as [50]
Citations
Cites
Ascioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Denning, D. W., Donnelly, J. P., Edwards, J. E., Erjavec, Z., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/323335 · Cited by 2,331 · cited 1×
“We only considered proven infection, based on the definitions of the Invasive Fungal Infection Cooperative Group of the European Organization for Research and Treatment of Cancer–Mycosis Study Group of the National Institute of Allergy and Infectious Diseases cooperative group [19]: fungemia, isolation from normally s…”
MethodNEW YORK STATE JOURNAL OF MEDICINE.
(1901) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1901.02470020041007 · Cited by 1,472
Rex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G., Walsh, T. J., et al. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.235 · Cited by 855
Medical Mycology. The Pathogenic Fungi and Pathogenic Actinomycetes.
(1976) · Annals of Internal Medicine · doi:10.7326/0003-4819-84-4-514_1 · Cited by 847
Viscoli, C., Girmenia, C., Marinus, A., Collette, L., Martino, P., Vandercam, B., Doyen, C., Lebeau, B., Spence, D., Krcmery, V., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/514731 · Cited by 601 · cited 1×
“Despite this spectrum of susceptibility, a favorable outcome was observed in 63% of cases revealed in our literature search, which is a slightly higher percentage than that reported for cases of invasive candidiasis [87].”
ResultProtection from gastrointestinal diseases with the use of probiotics
Marteau, P. R., Vrese, M. D., Cellier, C. J., & Schrezenmeir, J. (2001) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/73.2.430s · Cited by 596
Saccharomyces cerevisiae Fungemia: An Emerging Infectious Disease
Munoz, P., Bouza, E., Cuenca-Estrella, M., Eiros, J. M., Perez, M. J., Sanchez-Somolinos, M., Rincon, C., Hortal, J., & Pelaez, T. (2005) · Clinical Infectious Diseases · doi:10.1086/429916 · Cited by 462 · cited 1×
“35[77] 76 years, F DNA fingerprinting Diabetes, heart surgery No Yes Yes Yes FLU NS Death 36 [771 72 years, F DNA fingerprinting Heart surgery No Yes Yes Yes None NS Death 37 [77] 74 years, F DNA fingerprinting Rheumatoid arthritis, corticosteroid therapy, heart surgery NS No Yes Yes FLU NS Death”
BackgroundFUNGAL ENDOCARDITIS: ANALYSIS OF 24 CASES AND REVIEW OF THE LITERATURE
EUBINSTE1N, E., NOKIEGA, E. R., SIMBEEKOFF, M. S., HOLZMAN, E., & RAHAL, J. J. (1975) · Medicine · doi:10.1097/00005792-197507000-00003 · Cited by 275 · cited 1×
“1 [231 54 years, F Blood Urine Diphtheroids Valvular prosthesis No Yes Yes AmB Yes Favorable 2 [24] 38 years, M .”
BackgroundNew Spectrum of Fungal Infections in Patients with Cancer
Anaissie, E., Bodey, G. P., Kantarjian, H., Ro, J., Vartivarian, S. E., Hopfer, R., Hoy, J., & Rolston, K. (1989) · Clinical Infectious Diseases · doi:10.1093/clinids/11.3.369 · Cited by 259
Possible Role of Catheters in Saccharomyces boulardii Fungemia
Hennequin, C., Kauffmann-Lacroix, C., Jobert, A., Viard, J. P., Ricour, C., Jacquemin, J. L., & Berche, P. (2000) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s100960050003 · Cited by 253 · cited 5×
“Hand transmission has been suggested in these latter cases [5].”
BackgroundMethodInfluentialSelf-citation
Research works printed but not linked: 9
- 2001, 11, 19
- Rubinstein, 1975, Medicine, 54, 331
- Eschete, 1980, Archives of Internal Medicine, 140, 1539, 10.1001/archinte.1980.00330220085032 · doi:10.1001/archinte.1980.00330220085032
- 1997, Bulletin de la Soci t de pathologie exotique (1990), 90, 307
- Pavese, 1999, Pathologie-biologie, 47, 579
- Feld, 1982, The Journal of Rheumatology, 9, 637
- Kirsch, 1999, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie, 34, 229
- Zunic, 1991, Th rapie, 46, 498
- Pletincx, 1995, Journal of pediatric gastroenterology and nutrition, 21, 113, 10.1097/00005176-199507000-00022 · doi:10.1097/00005176-199507000-00022 · Paper page
Cited by
Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pepin, J., & Wilcox, M. H. (2010) · Infection Control & Hospital Epidemiology · doi:10.1086/651706 · Cited by 2,942
“boulardii has, however, been associated with fungemia in immunocompromised patients and in patients with central venous lines, and it should be avoided in critically ill patients.(227) There is no compelling evidence that other probiotics are useful in the prevention or treatment of recurrent CDI.”
McDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., Dubberke, E. R., Garey, K. W., Gould, C. V., Kelly, C., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix1085 · Cited by 2,690
Debast, S. B., Bauer, M. P., & Kuijper, E. J. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12418 · Cited by 1,215
“probiotics such as Saccharomyces boulardii in debilitated or immunocompromised patients [134,135].”
BackgroundCandida albicans Biofilms and Human Disease
Nobile, C. J., & Johnson, A. D. (2015) · Annual Review of Microbiology · doi:10.1146/annurev-micro-091014-104330 · Cited by 1,057
Epidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901
The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies
Zitvogel, L., Ma, Y., Raoult, D., Kroemer, G., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aar6918 · Cited by 777
Food fermentations: Microorganisms with technological beneficial use
Bourdichon, F., Casaregola, S., Farrokh, C., Frisvad, J. C., Gerds, M. L., Hammes, W. P., Harnett, J., Huys, G., Laulund, S., Ouwehand, A., et al. (2012) · International Journal of Food Microbiology · doi:10.1016/j.ijfoodmicro.2011.12.030 · Cited by 742
“This mycotoxin is unstable in cheese and is converted to PR-imine (Engel and Prokopek, 1979; Siemens and Zawistowski, 1993).”
BackgroundSystematic review and meta-analysis of Saccharomyces boulardii in adult patients
McFarland, L. V. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i18.2202 · Cited by 545
Arendrup, M. C., Boekhout, T., Akova, M., Meis, J. F., Cornely, O. A., & Lortholary, O. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12360 · Cited by 529
Changing epidemiology of systemic fungal infections
Richardson, M., & Lass-Flörl, C. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.01978.x · Cited by 524
“In a recent clinical review, 92 cases of Saccharomyces invasive infection were presented, only 15 of which were diagnosed before 1990 [56].”
BackgroundYarrowia lipolytica: Safety assessment of an oleaginous yeast with a great industrial potential
Groenewald, M., Boekhout, T., Neuvéglise, C., Gaillardin, C., van Dijck, P. W. M., & Wyss, M. (2014) · Critical Reviews in Microbiology · doi:10.3109/1040841x.2013.770386 · Cited by 498
(EFSA), E. F. S. A. (2007) · EFSA Journal · doi:10.2903/j.efsa.2007.587 · Cited by 479
Comprehensive polymorphism survey elucidates population structure of Saccharomyces cerevisiae
Schacherer, J., Shapiro, J. A., Ruderfer, D. M., & Kruglyak, L. (2009) · Nature · doi:10.1038/nature07670 · Cited by 453
Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Bijie, H., Dzierzanowska, D., Klimko, N. N., Letscher-Bru, V., Lisalova, M., Muehlethaler, K., et al. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.01747-08 · Cited by 370
“cerevisiae from clinical specimens may reflect the practice of using the organism (subtype boulardii) as a probiotic in the treatment of antibiotic-associated diarrhea (19, 38).”
BackgroundStrope, P. K., Skelly, D. A., Kozmin, S. G., Mahadevan, G., Stone, E. A., Magwene, P. M., Dietrich, F. S., & McCusker, J. H. (2015) · Genome Research · doi:10.1101/gr.185538.114 · Cited by 337
“cerevisiae also causes infections, the incidence of which has increased (Enache-Angoulvant and Hennequin 2005; Pfaller and Diekema 2010).”
InfluentialSaccharomyces boulardii: What Makes It Tick as Successful Probiotic?
Pais, P., Almeida, V., Yılmaz, M., & Teixeira, M. C. (2020) · Journal of Fungi · doi:10.3390/jof6020078 · Cited by 327
Treatment of Clostridium difficile Infection
Gerding, D. N., Muto, C. A., & Owens, Jr. (2008) · Clinical Infectious Diseases · doi:10.1086/521860 · Cited by 287
“boulardii in immunocompetent hosts and immunocompromised hosts [76-79].”
BackgroundProbiotics in Medicine: A Long Debate
Stavropoulou, E., & Bezirtzoglou, E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02192 · Cited by 282
“However, a study on the use of Saccharomyces boulardii in immunocompromised patients showed occurrence of invasive disease (81, 82).”
ResultGenome sequencing and comparative analysis of Saccharomyces cerevisiae strain YJM789
Wei, W., McCusker, J. H., Hyman, R. W., Jones, T., Ning, Y., Cao, Z., Gu, Z., Bruno, D., Miranda, M., Nguyen, M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701291104 · Cited by 252
Barlow, S., Chesson, A., Collins, J. D., Dybing, E., Flynn, A., Fruijtier-Pölloth, C., Hardy, A., Knaap, A. G. A. C., Schans, J., Silano, V., et al. (2007) · Cited by 232
Zhang, X., Li, B., Zhang, Z., Chen, Y., & Tian, S. (2020) · Journal of Fungi · doi:10.3390/jof6030158 · Cited by 222
Intestinal microbiome and fitness in kidney disease
Meijers, B., Evenepoel, P., & Anders, H.-J. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0172-1 · Cited by 224
Yeasts in foods and beverages: impact on product quality and safety
Fleet, G. H. (2007) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2007.01.010 · Cited by 220
Regulatory Oversight and Safety of Probiotic Use
Venugopalan, V., Shriner, K. A., & Wong-Beringer, A. (2010) · Emerging Infectious Diseases · doi:10.3201/eid1611.100574 · Cited by 216
The Occurrence and Prevention of Foodborne Disease in Vulnerable People
Lund, B. M., & O'Brien, S. J. (2011) · Foodborne Pathogens and Disease · doi:10.1089/fpd.2011.0860 · Cited by 212
“, 2006), and it is not clear whether it is a persistent commensal in the digestive tract or is only present transiently after ingestion of food (Enache-Angoulvant and Hennequin, 2005).”
BackgroundAndresen, V., Gschossmann, J., & Layer, P. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(20)30056-x · Cited by 206
Epidemiology of Infections in Cancer Patients
Zembower, T. R. (2014) · Cancer Treatment and Research · doi:10.1007/978-3-319-04220-6_2 · Cited by 190
“boulardii are rare but have increased among cancer patients since the 1990s [261].”
BackgroundThe involvement of gut microbiota in inflammatory bowel disease pathogenesis: Potential for therapy
Cammarota, G., Ianiro, G., Cianci, R., Bibbò, S., Gasbarrini, A., & Currò, D. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.006 · Cited by 180
“In addition, sepsis by S. boulardii, which is used in probiotic preparations to treat some types of diarrhoea, accounted for 51.3% of total fungaemias in a large French cohort (Enache-Angoulvant & Hennequin, 2005).”
BackgroundInfluentialProbiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders
Currò, D., Ianiro, G., Pecere, S., Bibbò, S., & Cammarota, G. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13632 · Cited by 160
“In particular, probiotics were associated with increased mortality rates in patients with severe acute pancreatitis (Besselink et al., 2008); moreover, S. boulardii was responsible for more than a half of total events of fungal sepsis in France (Enache-Angoulvant and Hennequin, 2005).”
BackgroundSinha, H., David, L., Pascon, R. C., Clauder-Münster, S., Krishnakumar, S., Nguyen, M., Shi, G., Dean, J., Davis, R. W., Oefner, P. J., et al. (2008) · Genetics · doi:10.1534/genetics.108.092932 · Cited by 152
Zhu, Y. O., Sherlock, G., & Petrov, D. A. (2016) · G3 Genes|Genomes|Genetics · doi:10.1534/g3.116.029397 · Cited by 145
“Virulent isolates are more likely to produce multiple distinct colony phenotypes as compared to avirulent isolates, which may contribute to their ability to survive in complex host environments (Clemons et al. 1996).”
Thompson, G. R., Cadena, J., & Patterson, T. F. (2009) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2009.02.001 · Cited by 172
Safety of Probiotics: Functional Fruit Beverages and Nutraceuticals
Žuntar, I., Petric, Z., Bursać Kovačević, D., & Putnik, P. (2020) · Foods · doi:10.3390/foods9070947 · Cited by 137
Huys, G., Botteldoorn, N., Delvigne, F., De Vuyst, L., Heyndrickx, M., Pot, B., Dubois, J., & Daube, G. (2013) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201300065 · Cited by 132
“boulardii (present in Enterol R ©) has been associated with cases of fungemia [128].”
BackgroundComparative genomics of wild type yeast strains unveils important genome diversity
Carreto, L. C., Eiriz, M. F., Gomes, A. C., Pereira, P. M., Schuller, D. E., & Santos, M. A. S. (2008) · BMC Genomics · doi:10.1186/1471-2164-9-524 · Cited by 134
“Indeed, a recent survey of 92 yeast invasive infections revealed that 50% of them were caused by Saccharomyces boulardii, which is used as a probiotic preparation for the treatment of antibiotic-related diarrhea [72].”
BackgroundDeep learning approach to describe and classify fungi microscopic images
Zieliński, B., Sroka-Oleksiak, A., Rymarczyk, D., Piekarczyk, A., & Brzychczy-Włoch, M. (2020) · PLOS ONE · doi:10.1371/journal.pone.0234806 · Cited by 126
Cruchet, S., Furnes, R., Maruy, A., Hebel, E., Palacios, J., Medina, F., Ramirez, N., Orsi, M., Rondon, L., Sdepanian, V., et al. (2015) · Pediatric Drugs · doi:10.1007/s40272-015-0124-6 · Cited by 122
“boulardii-related fungemia was reported in about 50 patients, with central venous catheterization as the main risk factor [170].”
BackgroundDugoua, J.-J., Machado, M., Zhu, X., Chen, X., Koren, G., & Einarson, T. R. (2009) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(16)34218-9 · Cited by 132
Qian, J. X., Cutler, J. E., Cole, R. B., & Cai, Y. (2008) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-008-2288-1 · Cited by 118
über, W. F. D. M. G. K. G. (2010) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-010-1028-9 · Cited by 133
Trubiano, J. A., Cheng, A. C., Korman, T. M., Röder, C., Campbell, A. J., May, M., Blyth, C. C., Ferguson, J., Blackmore, T., Riley, T. V., et al. (2016) · Internal Medicine Journal · doi:10.1111/imj.13027 · Cited by 128
Clinical Efficacy of Probiotics: Review of the Evidence With Focus on Children
(2006) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/01.mpg.0000239990.35517.bf · Cited by 115
Marson, G. V., de Castro, R. J. S., Belleville, M., & Hubinger, M. D. (2020) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-020-02866-7 · Cited by 124
“…that, in high-risk immuno-compromised or critically ill patients (in intensive care, with intravascular catheters and in previous antibiotic therapy), some strains have the ability to translocate across the gastrointestinal mucosa and progress to an infection (Enache-Angoulvant and Hennequin 2005).”
BackgroundBenedict, K., Chiller, T. M., & Mody, R. K. (2016) · Foodborne Pathogens and Disease · doi:10.1089/fpd.2015.2108 · Cited by 108
“We did not include cases of invasive Saccharomyces infection associated with probiotics in our review as the topic is comprehensively reviewed elsewhere (Enache-Angoulvant and Hennequin, 2005; Munoz et al. , 2005).”
The life and times of yeasts in traditional food fermentations
Tofalo, R., Fusco, V., Böhnlein, C., Kabisch, J., Logrieco, A. F., Habermann, D., Cho, G., Benomar, N., Abriouel, H., Schmidt‐Heydt, M., et al. (2019) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2019.1677553 · Cited by 116
Demırel, G., Erdeve, Ö., Çelik, İ. H., & Dilmen, U. (2013) · Acta Paediatrica · doi:10.1111/apa.12416 · Cited by 105
Gut microbiome dysbiosis is associated with increased mortality after solid organ transplantation
Swarte, J. C., Li, Y., Hu, S., Björk, J. R., Gaćeša, R., Vila, A. V., Douwes, R. M., Collij, V., Kurilshikov, A., Post, A., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn7566 · Cited by 112
Detection, Treatment, and Prevention of Clostridium difficile Infection
McCollum, D. L., & Rodriguez, J. M. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.03.008 · Cited by 98
Król, A., Railean‐Plugaru, V., Pomastowski, P., & Buszewski, B. (2019) · Phytochemistry Letters · doi:10.1016/j.phytol.2019.04.009 · Cited by 106
Opportunistic Strains of Saccharomyces cerevisiae: A Potential Risk Sold in Food Products
Pérez‐Torrado, R., & Querol, A. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.01522 · Cited by 111
Experimental Evolution Reveals Favored Adaptive Routes to Cell Aggregation in Yeast
Hope, E. A., Amorosi, C. J., Miller, A. W., Dang, K., Heil, C. S., & Dunham, M. J. (2017) · Genetics · doi:10.1534/genetics.116.198895 · Cited by 94
Diezmann, S., & Dietrich, F. S. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005317 · Cited by 104
“boulardii, that are used to treat antibiotic-related diarrhea, have been shown to cause a wide variety of infections, ranging from cutaneous infections and vaginitis to systemic infections of the bloodstream and vital organs in immunocompromised and immunocompetent individuals [20–33].”
BackgroundSafe and efficacious probiotics: what are they?
Reid, G. (2006) · Trends in Microbiology · doi:10.1016/j.tim.2006.06.006 · Cited by 113
“have also been seen in patients with inflammatory conditions of the intestine who received the high-dose, eight-strain probiotic VSL#3 [15], L. rhamnosus GG [16], Saccharomyces boulardii lyo [17], and even a Gram-negative probiotic, Escherichia coli Nissle 1917 [18] .N evertheless, invasive fungemias associated with S…”
BackgroundPericolini, E., Gabrielli, E., Ballet, N., Sabbatini, S., Roselletti, E., Cayzeele Decherf, A., Pélerin, F., Luciano, E., Perito, S., Jüsten, P., et al. (2017) · Virulence · doi:10.1080/21505594.2016.1213937 · Cited by 89
“safely used for human nutrition and health, and rarely reported to cause infection in highly predisposed, highrisk subjects.(33) The majority of studies performed with probiotic S.”
BackgroundClostridium difficile-Associated Disease: Changing Epidemiology and Implications for Management
Owens, R. C. (2007) · Drugs · doi:10.2165/00003495-200767040-00001 · Cited by 89
Safety assessment of dairy microorganisms: The hemiascomycetous yeasts
Jacques, N., & Casarégola, S. (2007) · International Journal of Food Microbiology · doi:10.1016/j.ijfoodmicro.2007.08.020 · Cited by 92
Cheng, A. C., Ferguson, J. K., Richards, M. J., Robson, J. M., Gilbert, G. L., McGregor, A., Roberts, S., Korman, T. M., & Riley, T. V. (2011) · Medical Journal of Australia · doi:10.5694/j.1326-5377.2011.tb03006.x · Cited by 87
Targeted Versus Universal Antifungal Prophylaxis Among Liver Transplant Recipients
Eschenauer, G. A., Kwak, E. J., Humar, A., Potoski, B. A., Clarke, L. G., Shields, R. K., Abdel-Massih, R., Silveira, F. P., Verhidis, P., Clancy, C. J., et al. (2015) · American Journal of Transplantation · doi:10.1111/ajt.12993 · Cited by 85
“cerevisiae has been reported to cause invasive infections in immunocompromised patients, but infections in LT recipients are exceedingly rare (36,37).”
BackgroundVentoulis, I., Sarmourli, T., Amoiridou, P., Mantzana, P., Exindari, M., Gioula, G., & Vyzantiadis, T. (2020) · Journal of Fungi · doi:10.3390/jof6030098 · Cited by 86
“prevention or treatment of various diarrheal disorders [11], it can cause several types of deep infections, most importantly fungaemia [9].”
BackgroundMethodInfluentialChilders, D. S., Raziunaite, I., Mol Avelar, G., Mackie, J., Budge, S., Stead, D., Gow, N. A. R., Lenardon, M. D., Ballou, E. R., MacCallum, D. M., et al. (2016) · PLOS Pathogens · doi:10.1371/journal.ppat.1005566 · Cited by 81
Segarra-Newnham, M. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1k110 · Cited by 74
de Llanos, R., Querol, A., Pemán, J., Gobernado, M., & Fernández-Espinar, M. T. (2006) · International Journal of Food Microbiology · doi:10.1016/j.ijfoodmicro.2006.04.023 · Cited by 73
Use of VSL♯3 in the Treatment of Rotavirus Diarrhea in Children: Preliminary Results
Dubey, A. P., Rajeshwari, K., Chakravarty, A., & Famularo, G. (2008) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31816fc2f6 · Cited by 72
Leaw, S. N., Chang, H. C., Barton, R., Bouchara, J., & Chang, T. C. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.00543-07 · Cited by 76
“Infections caused by non-Candida albicans and other less-common emerging yeasts, such as Cryptococcus, Pichia, Rhodotorula, Saccharomyces, and Trichosporon, have been widely reported in recent years (8, 12, 13, 19, 31, 33, 34, 45).”
BackgroundRannikko, J., Holmberg, V., Karppelin, M., Arvola, P., Huttunen, R., Mattila, E. J., Kerttula, N., Puhto, T., Tamm, Ü., Koivula, I., et al. (2021) · Emerging infectious diseases · doi:10.3201/eid2708.210018 · Cited by 76
“boulardii probiotic in preceding 7 d in control group‡ 4/76 (5) Central venous catheter 8 (17) Use of antimicrobial drugs in preceding 4 weeks 33 (72) Change in antimicrobial drugs because of fungemia 23 (50) Underlying diseases Digestive tract 27 (59) Neurologic 11 (24) Cardiovascular 8 (17) Solid tumor with metastas…”
BackgroundResultInfluentialTipping the balance both ways: drug resistance and virulence in Candida glabrata
Vale-Silva, L. A., & Sanglard, D. (2015) · FEMS Yeast Research · doi:10.1093/femsyr/fov025 · Cited by 67
“cerevisiae, only relatively rarely isolated as an infectious agent (Enache-Angoulvant and Hennequin 2005), and that of C.”
Seven cases of Saccharomyces fungaemia related to use of probiotics
Roy, U., Jessani, L. G., Rudramurthy, S. M., Gopalakrishnan, R., Dutta, S., Chakravarty, C., Jillwin, J., & Chakrabarti, A. (2017) · Mycoses · doi:10.1111/myc.12604 · Cited by 66
Diagnosis and Management of Clostridium difficile Infection
DuPont, H. L. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.03.016 · Cited by 69
Bretagne, S., Renaudat, C., Desnos‐Ollivier, M., Sitbon, K., Lortholary, O., Dromer, F., & on behalf of the French Mycosis Study Group (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx045 · Cited by 67
High-resolution mapping of cis -regulatory variation in budding yeast
Kita, R., Venkataram, S., Zhou, Y., & Fraser, H. B. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1717421114 · Cited by 63
“cerevisiae across a wide range of patient types and locations (44, 45).”
BackgroundGhelardi, E., Pichierri, G., Castagna, B., Barnini, S., Tavanti, A., & Campa, M. (2007) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2007.01872.x · Cited by 60
“cerevisiae has now been shown to behave as an opportunistic pathogen that is responsible for sporadic systemic infections [22].”
BackgroundClinical update for the diagnosis and treatment ofClostridium difficileinfection
Oldfield, E. C. (2014) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v5.i1.1 · Cited by 68
Treating Bugs with Bugs: The Role of Probiotics as Adjunctive Therapy for Helicobacter pylori
Wilhelm, S. M., Johnson, J. L., & Kale-Pradhan, P. B. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1q104 · Cited by 59
Arastehfar, A. A., Fang, W., Pan, W., Lackner, M., Liao, W., Badiee, P., Zomorodian, K., Badali, H., Hagen, F., Lass‐Flörl, C., et al. (2018) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2018.09.007 · Cited by 66
Cornet, M., Sendid, B., Fradin, C., Gaillardin, C. M., Poulain, D., & Nguyen, H.-V. (2011) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2010.11.014 · Cited by 59
“Beneficial effects of this pro-biotic strain remain controversial, as its ability to infect patients has been demonstrated in case of improper handling in the intensive care units.(52,53) Considering the unsolved question of the virulence of several S.”
BackgroundOwens, R. C. (2006) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.3.299 · Cited by 58
“boulardii.(72) To this end, probiotics at this juncture are not recommended at our institution.”
BackgroundDemırel, G., Çelik, İ. H., Erdeve, Ö., Saygan, S., Dilmen, U., & Canpolat, F. E. (2013) · European Journal of Pediatrics · doi:10.1007/s00431-013-2041-4 · Cited by 62
An oral vaccine against candidiasis generated by a yeast molecular display system
Shibasaki, S., Aoki, W., Nomura, T., Miyoshi, A., Tafuku, S., Sewaki, T., & Ueda, M. (2013) · Pathogens and Disease · doi:10.1111/2049-632x.12068 · Cited by 57
“However, whether it retains protective effect after attenuation of whole cells as in the previous study using another type of antigen-displaying cell (Adachi et al., 2010) needs to be examined, because S. cerevisiae sometimes causes invasive infection (Enache-Angoulvant & Hennequin, 2005).”
BackgroundThe forgotten role of food cultures
Bourdichon, F., Arias‐Roth, E., Babuchowski, A., Buckle, A. E., Bello, F. D., Dubois, A., Fontana, A., Fritz, D., Kemperman, R., Laulund, S., et al. (2021) · FEMS Microbiology Letters · doi:10.1093/femsle/fnab085 · Cited by 68
Nally, M. C., Pesce, V. M., Maturano, Y. P., Toro, M. E., Combina, M., de Figueroa, L. I. C., & Vázquez, F. (2013) · Postharvest Biology and Technology · doi:10.1016/j.postharvbio.2013.07.022 · Cited by 63
Nasirian, H. (2017) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2017.04.012 · Cited by 62
Probiotics in infectious diarrhoea in children: are they indicated?
Vandenplas, Y., Salvatore, S., Viera, M., Devreker, T., & Hauser, B. (2007) · European Journal of Pediatrics · doi:10.1007/s00431-007-0497-9 · Cited by 63
“Fungaemia with S. boulardii has been reported in about 50 patients [ 21 ].”
BackgroundProteomic Analysis of Pathogenic Fungi Reveals Highly Expressed Conserved Cell Wall Proteins
Champer, J., Ito, J. I., Clemons, K. V., Stevens, D. A., & Kalkum, M. (2016) · Journal of Fungi · doi:10.3390/jof2010006 · Cited by 59
“cerevisiae (“baker’s yeast”) was included because of the protective effect a heat-killed yeast antifungal vaccine has demonstrated previously [33,42–44], and because of growing numbers of reports of invasive Saccharomyces infections [45].”
BackgroundMuller, L. A. H., Lucas, J. E., Georgianna, D. R., & McCusker, J. H. (2011) · Molecular Ecology · doi:10.1111/j.1365-294x.2011.05225.x · Cited by 61
“…caused by S. cerevisiae warranted a reevaluation and this species is now regarded as an opportunistic pathogen of low virulence (de Hoog 1996; Enache-Angoulvant & Hennequin 2005). nce: John H. McCusker, Fax: +1 919 684 8735; s001@mc.duke.edu ress: Institut für Biologie – Botanik, Freie…”
BackgroundCommon Organisms and Probiotics: Saccharomyces boulardii
McFarland, L. V. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804024-9.00018-5 · Cited by 69
Rare fungal infectious agents: a lurking enemy
Skiada, A., Pavleas, I., & Drogari‐Apiranthitou, M. (2017) · F1000Research · doi:10.12688/f1000research.11124.1 · Cited by 53
Saccharomyces cerevisiae fungemia after probiotic treatment in an intensive care unit patient
Kara, İ., Yıldırım, F., ., O. O., Erganiş, S., Aydoğdu, M., Dizbay, M., Gürsel, G., & Kalkancı, A. (2017) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2017.09.003 · Cited by 48
Nutritional Yeast Biomass: Characterization and Application
Jach, M. E., & Serefko, A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811440-7.00009-0 · Cited by 59
Fluconazole Resistance in Isolates of Uncommon Pathogenic Yeast Species from the United Kingdom
Borman, A. M., Muller, J., Walsh-Quantick, J., Székely, A., Patterson, Z., Palmer, M. D., Fraser, M., & Johnson, E. M. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00211-19 · Cited by 58
“romyces cerevisiae (8, 41, 45, 46), Blastoschizomyces capitatus (47–49), Wickerhamiella (Candida) pararugosa (8, 50, 51), Dipodascus geotrichum (41), Starmerella (Candida)”
BackgroundMartin, I. W., Tonner, R. H., Trivedi, J. B., Miller, H., Lee, R., Liang, X., Rotello, L. C., Isenbergh, E., Anderson, J., Perl, T. M., et al. (2016) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2016.12.004 · Cited by 45
Fadhel, M., Patel, S., Liu, E., Levitt, M., & Asif, A. (2018) · Medical Mycology Case Reports · doi:10.1016/j.mmcr.2018.11.003 · Cited by 45
“boulardii was most likely to be found in patients with central venous catheters, digestive tract disease, ICU hospitalization, and those who are immunocompetent [7].”
BackgroundInfluentialPontes, A., Čadež, N., Gonçalves, P. M., & Sampaio, J. P. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00449 · Cited by 52
Saccharomyces cerevisiae biofilm tolerance towards systemic antifungals depends on growth phase
Bojsen, R., Regenberg, B., & Folkesson, A. (2014) · BMC Microbiology · doi:10.1186/s12866-014-0305-4 · Cited by 44
“cerevisiae has the potential to cause human infections [36] and its ability to adhere to plastic surfaces [28,30] makes it a relevant organism for the study of yeast biofilm tolerance towards antifungal agents.”
BackgroundFecal microbiota transplantation in gastrointestinal disease: 2015 update and the road ahead
Borody, T. J., Fischer, M., Mitchell, S., & Campbell, J. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2015.1086267 · Cited by 47
“Invasive saccharomyces has been reported from the use of probiotics [91]”
BackgroundKRINKO (2021) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-020-03265-x · Cited by 55
Polygenic cis-regulatory adaptation in the evolution of yeast pathogenicity
Fraser, H. B., Levy, S. F., Chavan, A. R., Shah, H., Pérez, J. C., Zhou, Y., Siegal, M. L., & Sinha, H. (2012) · Genome Research · doi:10.1101/gr.134080.111 · Cited by 47
“threatening infections have been reported, primarily in immunocompromised patients (Enache-Angoulvant and Hennequin 2005).”
BackgroundGuillemot, G., Despax, B., Raynaud, P., Zanna, S., Marcus, P., Schmitz, P., & Mercier‐Bonin, M. (2008) · Plasma Processes and Polymers · doi:10.1002/ppap.200700088 · Cited by 46
Cordell, B., & McCarthy, J. (2013) · International Journal of Clinical Medicine · doi:10.4236/ijcm.2013.47054 · Cited by 41
“cerevisiae has been described only recently as an “emerging infectious disease” [12,13].”
BackgroundSpinler, J. K., Ross, C. L., & Savidge, T. (2016) · Anaerobe · doi:10.1016/j.anaerobe.2016.05.007 · Cited by 46
Multidrug resistant (or antimicrobial-resistant) pathogens - alternatives to new antibiotics?
Brunel, A.-S., & Guery, B. P. (2017) · Swiss Medical Weekly · doi:10.4414/smw.2017.14553 · Cited by 47
Metadata
- Authors
- Enache-Angoulvant, A., & Hennequin, C.
- Affiliations
- Hôpital Tenon (FR)
- Corresponding author
- Hennequin, C.
- ORCID
- Hennequin, C.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-12-01
- Volume
- 41
- Issue
- 11
- Pages
- 1559-1568
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2168407031
- Cited by
- 369
- References
- 88
- Citations by year
- 2026: 12 · 2025: 13 · 2024: 10 · 2023: 17 · 2022: 14 · 2021: 17 · 2020: 24 · 2019: 19 · 2018: 23 · 2017: 34 · 2016: 19 · 2015: 23 · 2014: 14 · 2013: 23 · 2012: 18
- FWCI
- 1.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Keywords
- Saccharomyces cerevisiae, Saccharomyces boulardii, invasive candidiasis, fungemia, emerging fungal pathogens, amphotericin B susceptibility, fluconazole, central venous catheters, antibiotic therapy, immunocompetent patient
- MeSH terms
- Female, Humans, Male, Mycoses, Risk Factors, Saccharomyces
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.